Table 3.

Demographic summary by testing platform. (A) Xpert Xpress SARS-CoV-2 assay on the Cepheid GeneXpert Infinity platform, (B) Abbott RealTime SARS-CoV-2 assay on the Abbott m2000 platform, and (C) patients whose specimens were sent to a reference laboratory whereby a CT/CN value would not be available

A. Cepheid	Total number (%)	Average CT/CN value
African Americans	31 (77.5%)	28.1
Caucasian Americans	9 (22.5%)	24.37
Student’s T test (African Americans vs. Caucasian Americans) = p value of 0.26
	Total number (%)	Average CT/CN value
Males	38 (95%)	26.86
Females	2 (5%)	35
Student’s T test (males vs. females) = p value of 0.56
	Total number (%)	Average CT/CN value
<40 years of age	1 (2.5%)	19
40–49 years of age	2 (5%)	21.2
50–59 years of age	7 (17.5%)	28.53
60–69 years of age	14 (35%)	27.64
70–79 years of age	8 (20%)	28.9
>80 years of age	8 (20%)	27.25
B. Abbott	Total number (%)	Average CT/CN value
African Americans	84 (71.8%)	15.73
Caucasian Americans	25 (21.4%)	14.44
Other	8 (6.8%)	12.79
Student’s T test (African Americans vs. Caucasian Americans) = p value of 0.37
	Total number (%)	Average CT/CN value
Males	111 (94.9%)	15.07
Females	6 (5.1%)	18.77
Student’s T test (males vs. females) = p value of 0.35
	Total number (%)	Average CT/CN value
<40 years of age	9 (7.7%)	11.52
40–49 years of age	6 (5.1%)	16.59
50–59 years of age	25 (21.4%)	15.45
60–69 years of age	36 (30.8%)	15.56
70–79 years of age	26 (22.2%)	15.88
>80 years of age	15 (12.8%)	14.84
C. Test sent to reference lab	Total number (%)
African Americans	24 (80%)
Caucasian Americans	5 (1.7%)
Unknown/Declined to state	1 (3.3%)
	Total number (%)
Males	29 (96.7%)
Females	1 (3.3%)
	Total number (%)
<40 years of age	2 (6.7%)
40–49 years of age	2 (6.7%)
50–59 years of age	5 (16.7%)
60–69 years of age	7 (23.3%)
70–79 years of age	13 (43.3%)
>80 years of age	1 (3.3%)